Professor Peter Howe and Team to Present Significant Findings of New Long-Term Study of Resveratrol in Post-Menopausal Women

July 9th, 2019
|

July 9, 2019 – Evolva (SIX: EVE) is pleased to announce that Emeritus Professor Peter Howe from the University of Newcastle, Australia will present outcomes from the recently concluded RESHAW study (Resveratrol Supporting Healthy Aging in Women) at the 2nd Healthy Aging APAC summit, held July 9th-11th at the Hilton Singapore. This will be followed by presentations from Dr. Wong and PhD student Jay Jay Thaung Zaw at the Alzheimer’s Association International Conference, held July 14th -18th in Los Angeles.

The RESHAW study is a two-year clinical trial of resveratrol in 141 post-menopausal women. Led by Dr. Howe and Dr. Rachel Wong at the University’s Clinical Nutrition Research Centre, it is the largest, longest running study of its kind with resveratrol. Supported by Australia’s National Health and Medical Research Council, the Australian Research Council and a grant from Evolva, RESHAW was designed to investigate the impact of resveratrol supplementation on cognitive performance, along with a wide range of secondary outcomes including body composition and perceptions of wellbeing, physical function and pain.

Based on prior clinical studies by the team indicating that resveratrol may benefit cardiovascular, metabolic and brain health by improving circulatory function, RESHAW is also testing whether a low daily dose of resveratrol can boost blood flow in the brain, aid glucose metabolism and reduce postmenopausal bone and muscle loss. In a crossover comparison, volunteers were randomized to take two capsules containing 75mg of Evolva’s Veri-te™ resveratrol ingredient daily or a matching placebo supplement for 12 months, followed by the alternative treatment for a further 12 months.

“Unique aspects of this trial include the low dose of resveratrol which has proven both efficacious and safe in our prior studies”, commented Dr Howe, “and the long duration of the study which enables us to detect changes in body composition, particularly bone mineral density which is a major concern for older women”.

“With such a highly credentialed research team, Evolva saw the potential for rapid translation of the anticipated health outcomes of resveratrol supplementation and it is exciting to finally see the culmination of more than two years of research,” said Sally Aaron, SVP, Health Ingredients and Marketing. “Dr. Howe’s upcoming presentation in Singapore will provide the first look at the evidence that supplementation with Veri-te™ resveratrol can be a key strategy for the design and delivery of effective supplements that support healthy aging.”

“Our team’s dedication to the RESHAW study is now coming to fruition with the results pointing to multiple positive impacts of resveratrol for counteracting the development and progression of chronic diseases afflicting our aging Western population,” said Dr. Howe. “This bioactive polyphenol can be considered one of the most potent vasoactive nutrients that we have studied and we are excited to be finally previewing unpublished outcomes with my presentation at the Healthy Aging summit in Singapore, followed by presentations from Dr. Wong and PhD student Jay Jay Thaung Zaw at the Alzheimer’s Conference in Los Angeles.”

– ends –

About Veri-te™ resveratrol

Veri-teTM resveratrol offers customers a guarantee of quality together with strong scientific backing and versatility in application, which can both inspire and enable customers to develop innovative and award-winning products. www.veriteresveratrol.com

About Evolva

Evolva solves the supply chain issues of nature through a 21st century mix of biotechnology and fermentation. We develop, make and sell ingredients that provide significant health, wellness and nutrition benefits to people in their daily life, but whose supply chain issues have limited their use until now. Our flagship ingredients are stevia, nootkatone and resveratrol. To make our world sustainable requires nature and technology to work together as one, and our aim is to play a (small) part in achieving this transformation. For more information see www.evolva.com.

About University of Newcastle

The University of Newcastle is an institution dedicated to outstanding education and research, which is underpinned by a strong commitment to equity and excellence.

Currently 207th in the world by QS World University Rankings, we are consistently ranked within Australia’s top 10 universities.

We offer more than 250 undergraduate and postgraduate coursework programs and over 150 research masters and PhD programs across five Faculties – Business and Law, Education and Arts, Engineering and Built Environment, Health and Medicine, and Science.

We are proud to be the largest provider of enabling programs in Australia, and through the work of our Indigenous staff, communities and Elders, we have led Indigenous education for more than 30 years.

Across our campuses in Newcastle, the Central Coast, Port Macquarie, Sydney and Singapore, the University of Newcastle enrolls more than 37,000 students from diverse backgrounds, with a focus on developing the world’s next generation of socially-oriented leaders, entrepreneurs and innovators.

 Corporate Contact Details

David Tetzlaf

Marketing & Communications

davidt@evolva.com

+1 (619) 417-9531

This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.